Not Yet RecruitingNot Applicable

Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage

600 participantsStarted 2024-11-01

Plain-language summary

The objective of this study is to investigate the efficacy and safety of urapidil monotherapy versus the combination of esmolol in treating participants with acute hypertensive intracerebral hemorrhage through a prospective, open-label, observational, multicenter clinical trial, aiming to provide guidance for clinicians in formulating rational treatment plans.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants in the study of acute hypertensive intracerebral hemorrhage aged between 18 and 80 years old;
✓. Participants with acute intracerebral hemorrhage (basal ganglia hemorrhage \< 50ml) confirmed by imaging within 6 hours of onset;
✓. Participants with systolic blood pressure \> 140mmHg upon admission;
✓. Participants who have signed the informed consent form.

Exclusion criteria

✕. Participants in the cerebral hemorrhage study who decline to have their disease management information collected and used and/or refuse to undergo subsequent follow-ups;
✕. Participants with allergies to the medication in question;
✕. Participants in the study of secondary cerebral hemorrhage resulting from tumors, vascular malformations, aneurysms, trauma, post-thrombolytic therapy, or cerebral arteriovenous thrombosis;
✕. Participants undergoing anticoagulant therapy or with coagulation disorders;
✕. Pregnant women;
✕. Participants with multiple organ failure;
✕. Participants deemed unsuitable for enrollment by the research staff due to other factors.

What they're measuring

Modified Rankin Scale (mRS)

Timeframe: Three months after the onset of the disease

Trial details

NCT IDNCT06635707

SponsorQianfoshan Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11-01

Contact for this trial

Shaofeng Yan, postdoc

15662793799 2415@sdhospital.com.cn

View on ClinicalTrials.gov More Hypertensive Intracerebral Hemorrhage trials